The impact of chyawanprash on immunogenicity when administered after covid-19 vaccination in health care personnel - an open-label, prospective randomized controlled study - ECIVHCP

Central Council for Research in Ayurvedic Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.All healthcare professionals and staff of age group between 25 to 60 years, after 14 days of 2nd dose of COVID-19 vaccine (COVISHIELD), negative for SARS- Cov-2 at screening, (tested by rt-PCR), at DMIMS, without co-morbid condition or stable with ongoing medications, with exposure/chance of exposure to COVID 19 positive cases.
•2.Who is willing to provide signed informed consent
•High-Risk Group- It includes doctors, nursing staff, and other paramedical staff like attendants who are directly looking after and examining COVID patients.
•Low risk- other faculty members & hospital staff who are present in the institute but not visiting the corona ward.

•1.Not vaccinated with COVID-19 vaccine (1st and 2nd dose).
•2. Pregnant and lactating females.
•3.Immune compromised cases.
•4.Laboratory confirmed COVID-19 with or without symptoms
•5. Known allergy to any of the medications used in this trial.
•6. Not willing to participate in the study.
•7. History of receiving any investigational drug in the preceding one month.
•8.Subjects who are taking any other medicine as prophylaxis such as HCQ or any other CAM (Complimentary Alternative Medicine) formulation in the preceding 1 month.
•9.Any condition or circumstances which in the opinion of the investigator may make a participant unlikely or unable to complete the study or comply with study procedures and requirements

发起方